A definitive diagnosis of Alzheimer's diseases

( the florbetaben Phase III clinical trials )

PleaseHelpSupport Alzheimer's Research Today!
Your Alzheimer's donation will help billionslive without it. Donate online now

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

At present, diagnosis of Alzheimer's disease is based on cognitive tests that can only indicate a probability of having the disease. A definitive diagnosis of Alzheimer's disease is only possible through a post-mortem autopsy or brain tissue biopsy.

"We are pleased that with the initiation of the florbetaben Phase III clinical trials Bayer is moving forward on the development of a diagnostic tool that has the potential to enable a more definitive and earlier diagnosis of Alzheimer's disease," said Douglas Stefanelli, Vice President and General Manager, Diagnostic Imaging, Bayer HealthCare Pharmaceuticals. ...http://www.news-medical.net

Probiotic research needed to fulfill gut health potential

Probiotics should be considered as living drugs rather than “simple good bacteria” in order to become effective treatment options for IBS, according to Joseph Haddad, medical director of Institut Rosell-Lallemand. ...http://www.nutraingredients.com

Беларусь ТВ

Posted YVN